

00827T" 0854260

ID NO:4, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or
SEQ ID NO:10, which molecule (i) immunospecifically
binds CD40, (ii) increases the binding of CD40
ligand to CD40 by at least 45%, and (iii) comprises
one or more substitutions or insertions in primary
amino acid sequence relative to native monoclonal
antibody S2C6 as secreted by the hybridoma
deposited with the ATCC and assigned accession
number PTA-110, which amount is effective for the
treatment or prevention of an immune disorder.

31. A method for the treatment or prevention of an
immune disorder in a subject comprising:

administering to the subject an amount of a
purified protein, which protein (i) competes for
binding to CD40 with monoclonal antibody S2C6 as
secreted by the hybridoma deposited with the ATCC
and assigned accession number PTA-110, (ii)
increases the binding of CD40 ligand to CD40 by at
least 45%, and (iii) comprises one or more
substitutions or insertions in primary amino acid
sequence relative to native monoclonal antibody
S2C6 as secreted by the hybridoma deposited with
the ATCC and assigned accession number PTA-110,
which amount is effective for the treatment or
prevention of an immune disorder.

32. The method of any one of claims 26-31 further
comprising administering CD40 ligand to the subject.

33. The method of any one of claims 26-31 in which the
subject is a human.

34. The antibody of claim 3 which is not isotype IgG1.

35. A transgenic non-human animal, plant, or an
isolated cell containing one or more transgenes encoding a

protein, which protein competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, and which protein increases the binding of CD40 ligand to CD40 by at least 45%.

5

36. A pharmaceutical composition comprising in an amount effective for the treatment or prevention of cancer or an immune disorder, or for activating or augmenting an immune response: (a) a molecule that immunospecifically binds CD40, which molecule increases the binding of CD40 ligand to CD40; (b) CD40 ligand; and (c) a pharmaceutically acceptable carrier.

10

37. A method for the treatment or prevention of cancer or an immune disorder in a subject comprising administering to the subject, in an amount effective for said treatment or prevention: (a) a molecule that immunospecifically binds CD40, which molecule increases the binding of CD40 ligand to CD40; and (b) CD40 ligand.

15

20

25

30

35

Add A1
Add B3

008211 0054260